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A B S T R A C T
The SARS-CoV-2 virus is an etiological agent of pandemic COVID-19, which spreads rapidly worldwide. No
proven effective therapies currently exist for this virus, and efforts to develop antiviral strategies for the
treatment of COVID-19 are underway. The rapidly increasing understanding of SARS-CoV-2 virology provides a
notable number of possible immunological procedures and drug targets. However, gaps remain in our under-
standing of the pathogenesis of COVID-19. In this review, we describe the latest information in the context of
immunological approaches and emerging current antiviral strategies for COVID-19 treatment.
1. Introduction
In December 2019, many severe respiratory diseases accompanied
by pneumonia appeared in Wuhan, Hubei province, China, with un-
known etiology [1–3]. Sequencing examination on lower respiratory
tract specimens showed a novel coronavirus named 2019 novel cor-
onavirus (2019-nCoV) [4–8]. Data from genome sequencing of SARS-
CoV-2 assist the researchers in approving diagnostic examination, epi-
demiologic tracking, and advancement of preventive and curative
strategies [9]. The clinical sign of COVID-19 has a wide range from
moderate, self-restraint respiratory tract illness to acute progressive
pneumonia, multi-organ collapse, and death [9,10]. Up to the present,
there were no licensed therapies for the therapy of 2019-nCoV infec-
tion. After the rise of the SARS-CoV-1 in 2003, screening of licensed
drugs for the therapy of SARS led to the identification of some drugs (as
reviewed by Vijayanand and colleagues) [11], such as protease in-
hibitors, nucleoside analogs, intravenous immunoglobulins, con-
valescent sera, tumor necrosis factor-alpha blockers, interferons, tra-
ditional Chinese medicines, and glycyrrhizin. This virus causes SARS in
humans [11]. There are no confirmed efficacious treatments for the
COVID-19; however, researchers made much effort to develop antiviral
strategies for the treatment of COVID-19. This review will describe the
current evidence on significant proposed, repurposed, or experimental
therapies for COVID-19 and present a summary of contemporary clin-
ical experience and treatment guidelines for this new pandemic SARS-
CoV-2.
2. Immunological approaches
2.1. Human monoclonal antibody
Antibodies are an essential part of host immune reactions to viral
infection. Due to their unique maturation process, antibodies can
emerge extremely particular to viral antigens [12]. The first use of
immunoglobulins (antibodies) as a therapy opportunity for viral dis-
eases can be hunted back to the beginning 20th century, using sera of
infected people, who had improved from the same condition [13,14].
This natural therapy regimen (serum therapy), was slowly replaced by
immunoglobulins purified from merged sera, intravenous immune
globulin (IVIG) [15]. Notwithstanding the achievement of both serum
therapeutics and IVIG, no meaningful advancement was made to pro-
duce antibodies as therapeutics. The hybridoma technique was
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continuously launched, facilitating the separation of monoclonal anti-
bodies (mAbs) from immunized mice in 1975 [16]. Various approaches
have been established since the mid-1980s for the effective separation
of mAbs toward viruses of human and animal sources [12]. To date,
there are no confirmed vaccines or therapeutic medications that are
special to COVID-19. Preventing monoclonal antibodies (mAbs), owing
to their fantastic antigen specificity, is among the most suitable nomi-
nees for compensating viral infection [17]. Hence, recognizing and
cloning of mAbs that can accurately target viral superficies proteins to
hinder the viral entrance to host cells is an acceptable strategy for
blocking and handling COVID-19, mainly when effective vaccines and
therapeutics medications are unavailable in the outbreak of the COVID-
19 pandemic [18]. mAbs targeting exposed positions on viral outside
proteins are frequently identified as hopeful classes of drugs toward
infectious disorders and have conferred therapeutic potency for nu-
merous types of viruses [19,20]. Neutralizing antibodies produced
against coronavirus mainly target the spike (S) glycoproteins outside
the viral envelope that mediates entrance into host cells.
The S protein is composed of two functional subunits, which involve
cell binding (S1 subunit) and S2 subunit, which includes membrane
fusion. S1 subunit the main target of the humoral immune system, that
Potent neutralizing antibodies often produced against it [21–26]. A
recent report by Wang et al. has shown that human mAbs can neutralize
both SARS-CoV-2 and SARS-CoV in cell culture [27]. Another report
demonstrated that Chen and colleagues separated two human mAbs
employing SARS-CoV-2 RBD-specific memory B cells separated from
healed cases with COVID-19. These two mAbs could especially attach to
SARS-CoV-2 RBD, block the interplay within SARS-CoV-2 RBD and the
hACE2 receptor, and lead to potent neutralization of SARS-CoV-2 S
protein pseudotyped virus infection. Before-mentioned human anti-
SARS-CoV-2 RBD-ACE2 blocking mAbs are initially described and en-
dure transcendent hope to be employed as specific preventive and
therapeutic tools toward underway SARS-CoV-2 pandemic [18]. This
knowledge suggests that mAbs have a promising approach for tackling
the COVID-19 pandemic. The results of using mAbs are still premature,
and future studies will shed light on the feasibility of this type of bio-
logical therapy for patients with COVID-19 (Fig. 1) (Table 1).
2.2. Convalescent plasma (CP) therapy in severe COVID-19 patients
The sera separated to form recovered patients from the infectious
disease called Convalescent plasma, which has been employed to pre-
vent and treat various infectious illnesses for longer than one century.
Antibodies exist in immune or convalescent plasma, intercede their
curative effects through multiple mechanisms. The antibody can attach
to a given infectious agent by compensating its infectivity directly.
Another mechanism that antibody may also contribute to its ther-
apeutic effect includes complement activation, phagocytosis, and anti-
body-dependent cellular cytotoxicity. Non-neutralizing antibodies at-
tach to the infectious agent but do not intervene with their capacity to
replicate in-vitro systems may also participate in prevention and ex-
pedite the rehabilitation process [28,29]. Across the previous two
decades, convalescent plasma therapy has been successfully employed
to manage SARS, MERS, and the 2009 H1N1 pandemic with competent
potency and safety [30–33]. A meta-analysis of 32 investigations of
SARS-CoV and severe influenza virus infection explained a statistically
meaningful decline in the pooled odds of fatality following treatment
with convalescent plasma, contrasted with placebo or no treatment
[34]. However, convalescent plasma treatment was unable to con-
siderably enhance the durability of the Ebola virus infection, pre-
sumably due to the lack of data on neutralizing antibody titration for
stratified examination [35]. Because the virological and clinical fea-
tures share similarities between SARS-CoV-1, MERS, and SARS-CoV-2,
convalescent plasma treatment might be a confident strategy choice for
COVID-19 saving [36]. Patients who have healed from COVID-19 with a
huge neutralizing antibody concentration may be a precious donor
reservoir of convalescent plasma. It is worth mentioning that there are
potential safety concerns on convalescent plasma therapy, including
transmitting other infectious agents and a pathological event called
antibody-dependent enhancement (ADE) [37]. ADE attributes to a
means of how antibodies increasing throughout a previous infection
exacerbate clinical severity as an outcome of disease with a distinct
viral serotype. This event is famed for some viruses, prominently the
Dengue virus [38].
Although, in convalescent serum trials, attention, and alertness to
recognize any enhanced infection, evidence will be demanded. In a
recent report published in China, researchers revealed that in 10% of
patients, one dose of convalescent plasma (200 mL) was well-tolerated
and significantly increased or maintained neutralizing antibodies at
high levels, resulting in the disappearance of viremia within a week. It
can also modulate multiple parameters compared to pre-transfusion,
including decreased C-reactive protein and increased lymphocyte
numbers. Besides, convalescent plasma therapy in seven cases who had
the former viremia led to the disappearance of viremia (undetectable
viral load). Another finding that study was that convalescent plasma
treatment was well-tolerated and conceivably improved the clinical
symptoms, thereby neutralizing viremia in patients with severe COVID-
19. Finally, the authors of this study believe that further investigations
are wanted to define the optimal dose and clinical benefits of con-
valescent plasma therapy [39]. Future studies should analyze the effi-
ciency of convalescent plasma treatment in many patients, and the
potential risk of this therapeutic method must be deeply assessed
(Fig. 1) (Table 1).
2.3. Cytokines-targeted therapy for COVID-19
The increasing knowledge is regarding COVID-19 pathogenesis has
supported the role of excess inflammatory mediators in patients with
COVID-19. Patients' pathological characteristics with COVID-19 include
capillary leakage of liquid and entrance of inflammatory cells, in-
cluding T cells, neutrophils, and macrophages [40], referring a function
for chemokines and cytokines targeting vascular endothelium. The
concentration of pro-inflammatory cytokines, including IL-1, IL-6, TNF-
α, and IFN-γ, are elevated in the blood of cases infected with COVID-19
[3,41]. Recent studies report different cytokine profiles in patients with
severe COVID-19 [3,41–46]. In a study carried out by Huang and col-
leagues have revealed the higher concentration of IL-2, IL-7, IL-10, TNF,
G-CSF, IP-10; CXCL10, MCP-1 (CCL2) and MIP-1A (CCL3), but not IL-6,
in cases hospitalized in the intensive care unit (ICU) contrasted with
non-ICU patients (4). Another study confirmed that during acute
COVID-19 disease, some pro-inflammatory cytokines such as IL-1β, IL-
1Ra, IL-2R, IL-6, IL-8 (CXCL8), IL-17, IFN-γ, GM-CSF elevated [42–46].
In recent exciting research, the concentration of some cytokines/che-
mokines, including IL-6, IL-10, IFN-γ, TNF, and IP-10 in ICU patients
with COVID-19, have been higher than mild to moderate non-ICU pa-
tients [3,42–44]. Various strategies, including global targeting of the
inflammation or compensating a single crucial inflammatory marker,
are applied to cope with cytokine storm in COVID-19. Between key
cytokines, IL-6 has drawn significant attention levels, and antibodies
that hinder the IL-6 receptor (IL-6 antagonist, tocilizumab, and sar-
ilumab) are now following phase 2/3 clinical trials for the possible
therapy of COVID-19 [47]. Another hopeful strategy is targeting IFN-γ,
which has been remarked by beginning a clinical trial for JAK-STAT
inhibitor (ruxolitinib) for managing COVID-19 severity [48]. TNF
works upstream of IL-6, and anti-TNF treatments earlier revealed pro-
tecting impacts in deadly SARS-CoV disease [49]. A recent report by
Cavalli et al. have shown that the efficacy of anakinra (human inter-
leukin-1 receptor antagonist protein) was notably higher in subjects
with COVID-19 contrasted with those who received standard treatment
for three weeks, led to decreased levels of serum CRP, improved re-
spiratory function (72% vs. 50%), increased survival rate (90% vs.
56%). However, the study results demonstrated that bacteremia's risk
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was elevated in cases receiving anakinra than those receiving standard
treatment [50]. Although there is no particular antiviral medicine for
COVID-19, knowledge of cytokine storm mechanisms can help to
speculate possible therapeutic interventions (Fig. 1) (Table 1) [51].
2.4. Corticosteroids
It is alleged that corticosteroid treatment is not supported for viral
pneumonia [52]. Investigations have revealed that the use of systemic
corticosteroids for patients with SARS-CoV and MERS-CoV was corre-
lated with a higher fatality rate than patients under standard treatment
[53,54]. The same finding was described in cases with influenza virus-
associated pneumonia [55]. In a study performed by Matsuyama et al.
[56], they utilized the nasal administration of corticosteroids for pa-
tients infected with coronaviruses. They indicated that in the cell cul-
ture models, the inhaled form of corticosteroids, such as Ciclesonide,
could be useful for the treatment of coronaviruses. Ciclesonide exerts
antiviral and anti-inflammatory activity in in-vitro models [56].
Furthermore, there are some open clinical trials for the therapeutic
assessment of methylprednisolone on COVID-19 patients [57]. A sys-
tematic review study carried out by Tahvildari and colleagues [58],
shows that at least six different published studies on the effect of cor-
ticosteroids on COVID-19 patients. Also, Wu et al. [59] indicated that
the use of corticosteroids for patients with COVID-19 who developed
ARDS could lead to a better outcome and reduce the mortality rate.
These results indicate the necessity of checking the clinical conditions
of COVID-19 patients before prescribing corticosteroids. Finally, re-
cently, a case report study from Japan shows that orally inhaled ci-
clesonide alleviates the local inflammation in the lung of patients with
COVID-19 pneumonia and inhibits the propagation of the virus by an-
tiviral activity [60]. Further studies are required to unravel the precise
mechanism of corticosteroids in the exacerbation of patients with
COVID-19 (Fig. 1) (Table 1).
2.5. Mesenchymal stem cells (MSCs)
Mesenchymal stem cells (MSCs) are a subset of non-hematopoietic
adult stem cells, readily isolated from various tissues. They show im-
munoregulatory activity and could be employed for the tissue repair
process as they secrete paracrine factors [61]. Cell-based therapy, re-
markably stem cell therapeutics, has become an encouraging remedial
field, in which many perceive possibilities to cure deadly and in-
flammatory disorders [62,63]. Notwithstanding the notable progress of
stem cell-based treatment, immunogenicity, poor cell source, and moral
problems are deemed the main therapeutic approach restrictions.
Among these, MSCs have drawn much attention due to origin potential,
a high reproduction speed, having a low invasive method, and free of
moral problems. There is an extreme advantage in applying MSC
treatment in contrast with other approaches [64]. The results indicate
that following COVID-19 infection may start suppressing immune
overactivity in the human body. In patients infected with SARS-CoV-2,
the immune system generates massive volumes of inflammatory factors,
prompting cytokine storm in which the immune cells produce an ex-
treme amount of cytokines and chemokines [65]. Herein, it is the
opening of the MSC therapy strategy in the treatment of COVID-19
patients. MSC cure can limit the storm release of cytokines by the im-
mune system and raise endogenous restoration by regenerative features
of stem cells [66]. Recently, some countries, such as China, the USA,
Fig. 1. Schematic represents the action of the mechanisms of candidates' drugs for treatments COVID-19.
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Table 1
Presentation of immunological approaches and emerging drugs for select suggested COVID-19 treatments.
Drugs Mechanism of action In vitro In vivo and Trials or Clinical Experience note
Hydroxychloroquine (HCQ) Inhibit the fusion of the virus to the cell
membrane by modulation of the endosomal
pH
In Vero cells hydroxychloroquine was found to
be more potent than chloroquine to inhibit
SARS-CoV-2 [73,138]
HCQ could significantly shorten TTCR and
promote the absorption of pneumonia [139]
HCQ significantly associated with viral load
reduction/disappearance in COVID-19 patients
and its effect is reinforced by azithromycin [77]
HCQ no effect on intubation or death in patients
with COVID-19 [80]
HCQ did not substantially reduce symptom
severity in outpatients with early, mild COVID-
19 [82].
HCQ has no benefit in patients with mild Covid-
19 [83].
HCQ with or without azithromycin was not
significantly associated with differences in in-
hospital mortality [140]
HCQ alone or with azithromycin in patients with
COVID-19 was associated with a decline in
COVID-19 associated mortality[84].
Chloroquine phosphate Inhibit the fusion of the virus to the cell
membrane by modulation of the endosomal
pH
In vitro activity against SARS-CoV-2 in
infected Vero E6 cells reported; some evidence
it may block infection in Vero E6 cells exposed
to SARS-CoV-2 [75,104,138]
Clinical experience in treating pts with COVID-
19 accumulating; reports of possible clinical
benefits, including decrease in viral load and
duration of illness [53,71,75]
Favipiravir (FPV) RNA polymerase inhibitor In vitro evidence of activity against SARS-CoV-
2 in infected Vero E6 cells reported with high
concentrations of the drug [104,105,141]
FPV significantly improved the latency to relief
for pyrexia and cough [99]
FPV in patients with COVID-19 led to decrease of
viral load and significant improvement in chest
imaging compared with the control arm [98]
Remdesivir RNA polymerase inhibitor In Vero E6 cells remdesivir inhibits SARS-CoV-
2 replication [104,105]
Remdesivir was not associated with statistically
significant clinical benefits [107]
Clinical improvement was observed in 68% of
severe Covid-19 patients treated with remdesivir
in a cohort study [142]
Remdesivir was associated with shortened
recovery time and decreased rate of mortality in
patients with COVID-19 versus the placebo group
[109]
EIDD-2801 RNA polymerase inhibitor EIDD-2801 inhibits SARS-CoV-2 in human
airway epithelial cell cultures [143]
ACE Inhibitors ACE inhibitors or ARBs may effect in terms of
virus binding
Clinical trial underway: Initiation of losartan in
adult patients with COVID-19 requiring
hospitalization; primary outcome measure:
sequential organ failure assessment (SOFA)
respiratory score (NCT04312009)
hrsACE2 Inhibition of viral entry into the cell In vitro hrsACE2 had a dose dependent effect
of viral growth of SARS-CoV-2 and was able to
reduce it by a factor of 1,000 to 5,000 in cell
cultures [89]
Currently no known published data regarding
efficacy or safety in the treatment of COVID-19
Ivermectin Inhibiting IMPα/β1 which mediated nuclear
import of viral proteins in some human and
animal viruses.
In vitro activity against some human and
animal viruses
In vitro evidence of activity against SARS-CoV-
2 in infected Vero-hSLAM cells reported with
high concentrations of the drug [118]
Currently no known published data regarding
efficacy or safety in the treatment of COVID-19




In patients with SARS-CoV-2 infection, the use of
convalescent plasma was reported to increase
neutralizing antibody, decreased viral load, and
CRP, improve the clinical outcomes through
neutralizing viremia in severe COVID-19 cases
[39]
The recent retrospective study in 6 severs
COVID-19 patients were treated with
convalescent plasma at a median of 21.5 days
after the first detection of viral shedding.
Although viral clearance was observed in all
patients following transfusion, death occurred in
5 out of 6 patients [144]
In a descriptive study in china various
laboratory, radiologic, and clinical
improvements were improved in patients with
COVID-19 that received convalescent plasma
[145]
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Table 1 (continued)























Anakinra Recombinant human interleukin-1 (IL-1)
receptor antagonist, may potentially combat
cytokine release syndrome (CRS) symptoms
in severely ill patients
In patients with COVID-19, anakinra decreased
serum CRP, improvements in respiratory
function, and also the survival rate increased
about 90% [50]
Ruxolitinib Janus kinase (JAK) 1 and 2 inhibitor Phase 3 randomized, double-blind, placebo-
controlled clinical trial (NCT04362137;
RUXCOVID) evaluating ruxolitinib plus standard
of care vs standard of care alone is being initiated
in patients ≥ 12 years of age with COVID-19-
associated cytokine storm [9,146–148]








Tocilizumab Recombinant humanized monoclonal
antibody specific for the interleukin-6 (IL-6)
receptor
Case reports and observational investigations
describe the effectiveness of tocilizumab in
patients with COVID-19 described from various
areas of the world.
Currently, there are no well-controlled published
researches on the effectiveness and safety of
tocilizumab for the treatment of COVID-19;
however, various clinical trials are designed or
underway globally [9,149]
Siltuximab Recombinant chimeric monoclonal antibody
specific for the interleukin-6 (IL-6) receptor
Primary (non-peer-reviewed) judgments from an
observational case-control investigation of the
initial 21 patients withCOVID-19 and ARDS who
engaged in a compassionate treatment program
(SISCO study; NCT04322188) in one hospital
and were tracked for up to 7 days displayed
diminished and normalized C-reactive protein
(CRP) levels at day 5 in all 16 Siltuximab-treated
patients with adequate, accessible data. An
interim examination revealed that 33% of the
Siltuximab-treated patients recovered, and no
clinically related change in condition was
described in 43% of patients. In comparison,
24% of patients worsened, including one patient
who died and another with a cerebrovascular
occasion. This cohort investigation with patients
treated with standard therapy is continuing
[150]
Other clinical trial registered:
NCT04329650
NCT04330638
Corticosteroids Potent anti-inflammatory and antifibrotic
properties; use of corticosteroids may
prevent an extended cytokine response and
may accelerate resolution of pulmonary and
systemic inflammation in pneumonia
Uncontrolled observational data of the novel
COVID-19 outbreak in China propose a
reasonable treatment profit of
methylprednisolone in COVID-19 patients with
acute respiratory distress syndrome [59,151].
(continued on next page)
P. Goodarzi, et al. International Immunopharmacology 88 (2020) 106885
5
Table 1 (continued)
Drugs Mechanism of action In vitro In vivo and Trials or Clinical Experience note
Orally inhaled ciclesonide used in the case series
from Japan in COVID-19 patients with
pneumonia was associated with mitigating the
local inflammation and inhibit the proliferation
of the virus [60].
Other clinical trials have been launched in









Baricitinib Janus kinase (JAK) 1 and 2 inhibitor Currently, no known published controlled
clinical trial evidence confirming efficacy or
safety in patients with COVID-19
In a small (12 patients) open-label study in Italy
(NCT04358614), use of baricitinib in
combination with lopinavir/ritonavir was
assessed in patients with mild COVID-19
pneumonia [152]










Ibuprofen: Speculative link between
ibuprofen and increased ACE2 expression
leading to worse outcomes in COVID-19
patients, and should not be used in patients
with COVID-19 [153]
Indomethacin: Possible antiviral activity
against other coronaviruses SARSCoV
(interferes with viral RNA synthesis) [154]
In vitro activity against SARS-CoV [154]
Anticoagulants Modulate coagulation abnormalities A randomized open-label clinical trial
(NCT04345848) is currently being conducted to
evaluate prophylactic- and therapeutic-dose
anticoagulation in hospitalized adults with
severe COVID-19 infection
Neuraminidase inhibitors Antivirals active against influenza viruses In vitro investigations indicated oseltamivir
and zanamivir has inhibitory effects against
SARS-CoV in cell culture [155]
While oseltamivir is regarded to have been
broadly used for confirmed or suspect COVID-19
states in hospitals in China, there has been no
conclusive confirmation to date that oseltamivir
is beneficial in the treatment of COVID-19 [156]






HIV Protease Inhibitors Inhibits 3–chymotrypsin like protease Lopinavir (LPV) has in vitro activity against
SARS-CoV-2 in Vero E6 cells [157]
Atazanavir (ATV) alone or with ritonavir
(ATV/RTV) has in vitro activity against SARS-
CoV-2 in Vero E6 cells [157,158]
Nelfinavir, Saquinavir, and Tipranavir have n
vitro activity against SARS-CoV-2 in Vero E6
cells [157]
LPV and RTV randomized, open-label trial in
China in hospitalized adult patients with severe
COVID-19 infection compared LPV/RTV in
combination with standard care remark that
LPV–RTV treatment has no benefit beyond
standard care [159]
A retrospective cohort study in China evaluated
the use of LPV/RTV with or without umifenovir
in adults. The results of this study indicated that
the apparent favorable clinical response with
arbidol and LPV/RTV supports further LPV/RTV
only [160]
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Iran, and various other countries, have launched MSC therapy, and
some reports are currently available in the published literature. MSCs,
working their immunomodulatory features and their differentiation
capacity, can inhibit lung tissue loss by hindering the cytokine storm
and restoration and regeneration of damaged tissues [67]. A recent
study carried by Chen and co-workers indicated that the use of MSCs
notably improves the survival proportion of H7N9-induced ARDS and
provides a philosophical background for treating H7N9-induced ARDS
preclinical research and clinical research. Because H7N9 and COVID-19
share similar complications and are associated with multi-organ col-
lapse, MSC-based treatment could be a feasible option for the treatment
of COVID-19 [68]. In the same way, a recent case-report study showed
that the adoptive transfer therapy of human umbilical cord blood de-
rived-mesenchymal stem cells (hUCMSCs) to a Chinese female patient
afflicted with acute COVID19 syndromes improved her laboratory tests
and CT images [69]. Before receiving any treatments, the percentage of
her neutrophils was increased to 87.9% while the number of lympho-
cytes was decreased to 9.8%. She was operated with antiviral medica-
tions, including lopinavir/ritonavir, IFN-α, and oseltamivir, also the
intravenous dose of moxifloxacin, xuebijing, methylprednisolone, and
immunoglobulins. The case was also curbed to non-invasive mechanical
ventilation to expedite breathing and decrease muscle weakness due to
weak oxygenation. As the vital symptoms exacerbate, the case was
treated with hUCMSCs solely and with α1 thymosin 5 × 107 cells per
three times. The study results explained that following the second in-
jection, serum albumin, CRP, ALT, and AST were steadily diminished,
and other important symptoms were enhanced. After that, the patient
was discharged from the ventilator and capable of walking, and the
number of neutrophils and white blood cells returned to the baseline
levels. Most importantly, the abundance of CD3+, CD4+, and
CD8 + T cells was significantly enhanced. Also, the qualitative out-
comes of CT images following the second and third doses of hUCMSCs
revealed that pneumonia was attenuated. After two days of the third
injection, the patient was rescued from the ICU, and most of the vital
symptoms and clinical laboratory parameters returned to the standard
ranges. The outcomes recommended that hUCMSCs could be an ex-
cellent strategy choice alone or in combination with other im-
munomodulatory tools for COVID-19 patients [69]. A recent study
performed in China in cooperation with the United States recruited
seven cases with COVID19 pneumonia from January 23 to February 16.
Patients experienced MSCs transplantation, and their clinical signs were
consecutively checked for 14 days. The study demonstrated that the
transplantation of hUCMSCs led to a marked decrease in the level of
pro-inflammatory cytokines and a substantial improvement in clinical
symptoms without any significant adverse effects [70]. The pulmonary
function, along with the seven patients' clinical symptoms, were sig-
nificantly improved after two days of transplantation. The number of
peripheral lymphocytes also increased, while CRP concentration was
diminished after the treatment. Additionally, the number of hyperactive
cytokine-secreting immune cells, namely CXCR3 + CD4+,
CXCR3 + CD8+, and CXCR3 + NK cells was remarkably lowered
within 3–6 days after transplantation of hUCMSCs. Moreover, the fre-
quency of CD14 + CD11c + CD11b mid regulatory DC cell population
was significantly elevated. The level of TNF-α was significantly re-
duced, while IL-10 was raised in the hUCMSCs-treated group contrasted
with the placebo control group. Besides, the gene expression char-
acterization explained that ACE2 and TMPRSS2 genes are not expressed
in hUCMSCs, implying that the coronavirus would not infect these cells.
Hence, the intravenous transplantation of hUCMSCs is seemingly safe
and efficient for the treatment of cases with COVID-19 pneumonia,
notably those in critically severe conditions [70].
As multiple clinical trials are launched worldwide, we should not
have to wait long to determine if MSCs are a viable and valid treatment
choice for severe COVID-19. Considering the need for mitigating the
prevailing COVID-19 pandemic, with superiority to manage fatality as
low as possible, the judgment that MSC is reliable and can invert severe
critical disease with high power is an invention designing a completely
novel biological procedure that needs to be developed urgently(Fig. 1)
(Table 1).
3. Other pharmacologic therapies
3.1. Chloroquine and hydroxychloroquine (HCQ)
Chloroquine and HCQ are both known as antimalarial drugs.
Clinical studies introduced these two drugs as a possible choice for
COVID-19 treatment due to having in-vitro antiviral and anti-in-
flammatory properties [71–74]. Several studies suggested that chlor-
oquine could improve the radiological and virological features of
COVID-19 [53]. Chloroquine is a reliable and effective drug for COVID-
19 in some preclinical trials [75] and other studies [72]. In this regard,
Smith et al. [72] indicated that cardiac arrhythmia is a significant side
effect of chloroquine. In the matter of hydroxychloroquine, reports are
controversial [72,73,76]. In a study conducted by Shamshirian et al.
[76], there was no potential clinical efficacy in prescribing HCQ. Si-
multaneously, the in-vitro anti-SARS-CoV-2 activity of this particular
drug seems to be more than chloroquine [72,73]. Fortunately, there are
currently several clinical trials being conducted on these drugs [57].
Also, regardless of the solo practice for these drugs, Gautret, and col-
leagues [77] suggested a combination of HCQ and azithromycin as an
effective treatment for decreasing the viral load in patients with COVID-
19. Another aspect of these drugs is the possibility of using them in
different conditions such as pregnancy. A majority of studies conducted
on HCQ did not reflect any serious concerns, and this drug seems to be
safe for pregnant women [78]. Besides, as mentioned by Lother et al.
[79], clinical trials for the assessment of medicines as post-exposure
prophylaxis could be helpful.
A recent report noted that the severity of COVID in patients treated
with HCQ was higher than those not receiving this medication. Also,
the report showed that there was no meaningful correlation within the
use of HCQ and intubation or mortality [80]. Besides, another report
demonstrated that amongst cases hospitalized in metropolitan New
Table 1 (continued)
Drugs Mechanism of action In vitro In vivo and Trials or Clinical Experience note
A retrospective investigation in China suggests
that patients with severe COVID-19 infection or
notably elevated levels of D-dimer may have
diminished mortality if given prophylactically;
however, the current study has limited data
[137]
A randomized open-label clinical trial is
currently being administered to assess preventive
and therapeutic dose anticoagulation agents in
hospitalized adult patients with severe COVID-19
infection:
NCT04345848
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York with COVID-19, practice with HCQ, azithromycin, or both, mat-
ched with neither medication, was not meaningfully correlated with
variations in an in-hospital fatality. However, the analysis of these
conclusions may be restricted by the observational study [81]. The
recent study also indicated that HCQ did not substantially decrease
symptom severity in outpatients with early, mild COVID-19 [82]. At the
same time, another study performed by Mitjà and colleagues indicated
that HCQ in patients with mild COVID-19 has no benefit beyond routine
care [83]. Moreover, Arshad and co-workers [84] showed that in pa-
tients with COVID-19 treated with HCQ alone and combined with azi-
thromycin, it was correlated with a decline in COVID-19 associated
mortality. Comprehensive systematic review and meta-analysis studies
and clinical trials in this field are urgently needed (Fig. 1) (Table 1).
3.2. ACE inhibitors and hrsACE2
ACE2 (angiotensin-converting enzyme-2) is a transmembrane en-
zyme expressed on the exterior of epithelial cells in the many organs
such as lungs, arteries, heart, kidney, and intestines [85,86]. Recently,
the new coronavirus is responsible for pandemic COVID-19, SARS-CoV-
2 is thought to be mainly or exclusively bound to ACE2 [87,88]. The
molecular interplay among ACE2 and spike has been created [87,88],
and manufactured compounds or antibodies, interfering with the in-
terplay of ACE2, and the viral spike protein could be produced. Another
therapeutic approach is the use of soluble ACE2 as a virus scavenger
and neutralizer. Soluble ACE2 formed by a proteolytic splitting of the
membrane anchor is ordinarily located in the plasma; however, its
concentration is shallow. An increase in the availability of soluble ACE2
at tissue positions would change the rivalry with membrane-bound
ACE2 toward the soluble form, leading to the repression of viral entry
into the cells. It is also expected that this approach would preserve
tissue ACE2 [89,90]. A new study has recently shown that the re-
combinant form of ACE2 reduces the infection and viral growth in cell
culture and organoids by acting as a decoy for SARS-CoV-2 [89]. This
study showed that by adding a genetically altered variant of ACE2,
termed human recombinant soluble angiotensin-converting enzyme 2
(hrsACE2), the entry of COVID-19 into the lung epithelial cells was
halted. In this study, the results of cell culture indicated that hrsACE2
decreased the load of SARS-CoV-2 by 1000–5000 times [89]. The au-
thors also used the blood vessels and kidney organoids to explain that
SARS-CoV-2 could directly contaminate and propagate in these tissues,
suggesting a potential agent of multi-organ collapse and cardiovascular
damages as a result of COVID-19. The augmentation of hrsACE2, too,
diminished the infectivity of SARS-CoV-2 in these organoids [89]. In
engineered models of the human blood artery and kidney organoids
developed from human stem cells, it was confirmed that it could
straight contaminate and replicate itself in these tissues. These findings
provide crucial information about the pathogenesis of COVID-19 and
explain the reason for multi-organ collapse and cardiovascular injuries.
In this engineered human tissues, hrsACE2 also diminished the viral
load of SARS-CoV-2. The researchers highlighted that their experiment
has only tested the drug efficacy through the initial stages of SARS-CoV-
2 infection. Further investigation would be demanded to determine the
fidelity of this recombinant therapy for later stages of the disease
(Fig. 1) (Table 1).
3.3. Ribavirin
The prescription of ribavirin for the therapy of coronaviruses re-
turns to SARS-CoV and MERS-CoV. Reports indicated that this antiviral
agent's administration did not show promising results for the treatment
of SARS-CoV [91]. Meanwhile, ribavirin antiviral activity was ad-
dressed in in-vitro studies in a dose-dependent manner [91,92]. On the
other hand, a group of studies demonstrated a beneficial role of riba-
virin in the treatment of MERS-CoV [93]. Simultaneously, some in-
vestigations showed that the combination of ribavirin and interferon
was unsuccessful in treating MERS-CoV [94]. There is limited knowl-
edge about the efficiency of ribavirin in the amelioration of COVID-19
[58]. A study conducted by Elfiky et al. [95], using bioinformatics ap-
proaches, indicated that ribavirin is capable of halting the viral spread
of SARS-CoV. Also, based on a study performed by Khalili et al. [96],
there are six clinical trials currently assessing the therapeutic effects of
ribavirin on COVID-19. Three clinical trials are presently being con-
ducted in China, while the other three clinical trials focused on the
combinatory role of ribavirin and other medicines, such as interferons
and lopinavir/ritonavir (Fig. 1) (Table 1) [96].
3.4. Favipiravir
Favipiravir (also known as T-705) is an antiviral drug that selec-
tively and robustly hinders the RNA-dependent RNA polymerase
(RdRp) of RNA viruses, was licensed in 2014 in Japan to cure pandemic
influenza virus diseases [97]. Interestingly, despite its anti-influenza
virus activity, this molecule can also halt the replication of an extensive
range of RNA viruses (e.g., flaviviruses, alphaviruses, filoviruses, nor-
oviruses, arenaviruses, bunyaviruses, and other RNA viruses) [97].
Regarding the emergence of SARS-CoV-2, it is urgently essential to
recognize active antiviral agents to fight the infection and investigate
the clinical effects of antiviral drugs. Recently, a clinical trial conducted
by Cai et al. highlighted the efficiency of favipiravir in patients with
COVID-19 [98]. They indicated that patients receiving favipiravir
showed improved chest imaging, faster decreased viral load, and fewer
adverse effects than the control group [98]. Another study performed
by Chen et al. compared the efficacy of favipiravir versus arbidol [99].
They showed that the clinical recovery rate on day seven and the degree
of auxiliary oxygen treatment or non-invasive mechanical ventilation
did not significantly vary within the favipiravir- and arbidol-treated
groups. Besides, the current study demonstrated that favipiravir sig-
nificantly enhanced the latency to relief for fevers. Also, adverse effects
caused by favipiravir were mild and manageable [99]. These pre-
liminary clinical results provide useful information about therapeutic
options for SARS-CoV-2 infection (Fig. 1) (Table 1).
3.5. Remdesivir
Remdesivir (GS-5734) is a prodrug (nucleotide) with extensive an-
tiviral action toward viruses from distinct genera in-vitro [100]. It also
has therapeutic effects on nonhuman primate models of deadly Ebola
and Nipah virus contaminations [101,102]. Investigations conducted
on epithelial cells from human airway explained that remdesivir ad-
ditionally hinders replicating an extensive range of coronaviruses, in-
cluding MERS-CoV [103]. Moreover, some reports indicated that re-
mdesivir has robust action toward SARS-CoV-2 in-vitro [104,105].
A recent investigation performed on Rhesus macaques con-
taminated with SARS-CoV-2 noted that the treatment with a 6-day re-
gimen of IV remdesivir launched 12 h following virus inoculation was
correlated with some therapeutic outcomes (lower disease severity
rates, less pulmonary infiltrates, lower virus titers in bronchoalveolar
lavage samples) contrasted with the control animals. Of note, re-
mdesivir medication did not diminish the viral load or the titer of the
virus in the nasopharynx or rectal swabs compared to the control of
vehicle control [106]. Various clinical trials are currently being per-
formed in the US, China, and other countries. A recent clinical trial in
hospitalized patients with severe COVID-19 in China showed that re-
mdesivir treatment was not correlated with a decline in hospitalized
patients' recovery period. The results indicated that patients receiving
remdesivir had a lower period of hospital stay than those receiving
placebo (18 vs. 23 days); however, such a reduction in hospital stay
period was not statistically significant. Also, the continuation of in-
vasive mechanical ventilation was more concise (but not statistically
meaningful) in the remdesivir-treated group, and only a tiny percentage
of patients (0.4%) underwent invasive mechanical ventilation at the
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time of reception. Remdesivir did not significantly reduce the viral load
of SARS-CoV-2 in nasopharyngeal, oropharyngeal, and sputum speci-
mens. Remdesivir was stopped in 18 patients (12%) because of adverse
effects [107]. However, a phase III randomized, open-label trial per-
formed on hospitalized patients with severe COVID-19 showed that the
disease severity was lower in patients who received remdesivir within
10 days after the onset of clinical symptoms compared with those
treated after 10 days of the manifestation of clinical signs [108]. No-
tably, patients treated with remdesivir had a more short recovery
period than those treated with placebo. Also, the mortality rate in re-
mdesivir-treated patients (7.1%) was lower than patients receiving a
placebo. However, the difference in mortality rate within the two
groups was not statistically meaningful [109]. Another clinical trial has
been recently established in the US, China, and other countries to ex-
plore the efficacy of remdesivir in improving patients with COVID-19
(Table 1). Further clinical trials are wanted to determine the effect of
remdesivir on patients with COVID-19 (Fig. 1) (Table 1).
3.6. Ivermectin
Ivermectin is an FDA-licensed drug that has a broad spectrum of
antiparasitic activity [110]. Studies have shown that this drug exerts
antiviral action toward an extensive range of viruses in-vitro
[111–114]. It has been designated that ivermectin hinders the interplay
within the human immunodeficiency virus-1 (HIV-1) integrase protein
(IN) and importin (IMP) α/β1 heterodimer accountable for the nuclear
import of IN [115]. Ivermectin has, too, been demonstrated to impede
nuclear import and HIV-1 replication [114]. Also, ivermectin sup-
presses explicitly the activity of the NS3 helicase enzyme, required for
the replication of flaviviruses [116].
In the same way, ivermectin inhibits the replication of dengue virus
type 2 (DENV-2) in Aedes albopictus [117]. Another study indicated
that ivermectin prevents the interaction between DENV 1 and 2 NS5
with its nuclear transporter importin α/β in-vitro and make effort
protection toward DENV1-4 [113]. Ivermectin is thought to be effective
against SARS-CoV-2, the virus which causes pandemic COVID-19 [118].
It has been reported that ivermectin can reduce the replication of SARS-
CoV-2 when added to the cell culture 2 h post-infection. Besides, iver-
mectin can diminish the viral load by ~5000 folds, whiting 48 h post-
infection [118]. The next critical step is to examine dosing regimens
that mimic the currently recommended use of ivermectin in humans
[119]. A current phase III clinical trial in Thailand showed that iver-
mectin was safe but did not perform any clinical advantage when used
for dengue viruses. However, studies recommended that dosing regi-
mens might be improved and expanded, depending on pharmacokinetic
analyses [120]. Although DENV differs from SARS-CoV-2, the design of
future clinical trials should be revisited to provide valuable information
about the efficacy of this drug on COVID-19. Current studies hold great
promise for the prescription of ivermectin as a possible antiviral
therapy against SARS-CoV-2 (Fig. 1) (Table 1).
3.7. Eidd-2801
β-D-N4-hydroxycytidine is a ribonucleoside analog called EIDD-
1931, an orally bioavailable prodrug by wide range antiviral action
toward multiple independent RNA viruses, which includes influenza,
Ebola, coronaviruses, and VEEV [121–124]. Currently, there are no
specific licensed therapeutics for SARS-CoV-2. Recently, an interesting
study indicated the efficacy of EIDD-2801against COVID-19 in human
cells and mice [123]. EIDD-2801 is an orally bioavailable drug that its
mechanism of action is similar to remdesivir. These drugs can mimic
the function of ribonucleosides, the fundamental elements of RNA
molecules, making devastating failures when the drugs are combined
into viral RNA throughout replication, halting the spread of the virus.
However, investigators recommend EIDD-2801 may have some bene-
fits. According to the results of Urakova et al., when EIDD-2801 is used
as a prophylactic agent, it would be capable of preventing severe lung
injury in infected mice. Besides, in therapeutic administration, it can
reduce the viral load and body weight loss if prescribed within 12 and
48 h of infection. This study highlights the potential efficacy of EIDD-
2801 for the treatment of SARS-CoV-2 and severe infections caused by
other types of coronaviruses [123]. Clinical trials seem to be needed to
investigate the probable applicability of EIDD-2801 in the clinic against
pandemic COVID-19 (Fig. 1) (Table 1).
3.8. Lopinavir/Ritonavir
Lopinavir and ritonavir are the HIV-1 FDA approved drugs, which
inhibitors of the HIV protease. This anti-protease activity seems to be
active on the SARS-CoV-2 protease, either. Lopinavir and ritonavir
could induce adverse effects, such as QT prolongation, and must be
carefully prescribed for patients with liver-associated diseases [72].
Several clinical trials conducted on the combinatory use of lopinavir/
ritonavir was more pronounced in patients with COVID-19 than other
therapeutic regimens [57,58]. One study also showed that the combi-
nation of lopinavir/ritonavir and arbidol (an antiviral agent against
RNA viruses) did not significantly protect COVID-19 in patients [125].
Meanwhile, Zhu and colleagues [126] demonstrated that arbidol
monotherapy was more effective than the use of lopinavir/ritonavir and
arbidol. Besides, an in-vitro study performed on lopinavir did not ex-
hibit any direct antiviral activity against SARS-CoV-2 [74]. Regardless
of these findings, the administration of lopinavir/ritonavir seems ben-
eficial on SARS-CoV and MERS-CoV only when used at the early stage
of infection [127]. In conclusion, it seems hard to introduce the lopi-
navir/ritonavir as a treatment option for COVID-19, but further clinical
trials are warranted to elucidate the effectiveness of these drugs (Fig. 1)
(Table 1).
3.9. Anticoagulation for COVID-19
There is progressing proof that cases with severe COVID-19 promote
a hypercoagulable status, which has been correlated with weak out-
comes such as increased respiratory malfunction, severe respiratory
distress syndrome, or mortality [128–134]. The initial treatment with
anticoagulation drugs in patients with severe COVID-19 infection may
diminish the risk of thrombotic complexities and promote clinical
consequences [59,129,131,133,135].
This increasing evidence urged researchers to focus on the potential
applicability of using anticoagulating agents for COVID-19. Heparin is
an anticoagulant agent possessing potential benefits beyond antic-
oagulant activity. It has been shown that heparin decreases coronary
thrombosis, pulmonary emboli, and microvascular ischemia. Besides, it
has anti-inflammatory and antiviral properties, enabling this compound
to lower the degree of lung inflammation and improving oxygenation
[136]. A new retrospective report by Tang et al. confirmed that antic-
oagulant therapy is correlated with a diminished mortality percentage
in COVID-19 patients with coagulopathy. Also, the results recommend
that patients with severe COVID-19 disease or considerably elevated
levels of D-dimer (> 6 × ULN) may have declined fatality when they
receive preventive doses of heparin. Researchers also proposed that
anticoagulant treatment seems to be correlated with a more favorable
prediction in severe COVID-19 patients engaging sepsis-induced coa-
gulopathy (SIC) standards extended D-dimer [137]. However, pro-
spective studies are demanded to validate these conclusions because the
current retrospective study has limited data (Fig. 1) (Table 1).
4. Conclusion
COVID-19 pandemic is an unexpected infectious disease with ex-
tensive mortality and morbidity rates that humanity has experienced in
the 21st century after the pandemic influenza outbreak of 1918.
Although the gaps remain in our understanding of the pathogenesis
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COVID-19, the velocity and mass of antiviral strategies began to ex-
amine possible medicines for COVID-19 to highlight both the demand
and capacity to provide high-quality data even amid a pandemic.
Probably the best plan for fighting with the SARS-CoV-2 is an effective
vaccine, which prompts the immune system to produce antibodies
against viral proteins or T cells that can eliminate infected cells.
However, vaccine development is slower than the spread of the epi-
demic; therefore, the clinically useful candidate drugs would be ne-
cessary and urgent for the treatment of patients with COVID-19. Among
the immunological approaches, CP therapy might be a trusting ap-
proach choice for COVID-19 saving; however, future investigations
should examine the efficacy of CP treatment in many patients, and the
potential risk of this therapeutic approach must be profoundly eval-
uated. Besides, many clinical trials are underway across the world;
however, currently, no therapies have been shown useful to date for
COVID-19, or some drugs such as remdesivir have a limited benefit in
patients with COVID19.
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